OneMedNet adds partner to combine clinical records with patient-journey data
Reported by Stock Titan, Investing.com Canada, Markets Insider and 1 more outlets4 sources ↓
OneMedNet says its 13th channel partner will pair its medical records with billing and pharmacy data for patient-journey analytics.
Key points
- The partner will resell OneMedNet’s de-identified clinical data alongside its own patient-journey data
- OneMedNet says its data network covers more than 2,300 healthcare sites, 90 million patient journeys and 270 million studies
- OneMedNet says the agreement has added about 25% to its sales funnel
Sources
- Stock TitanRead ↗A partner will pair OneMedNet medical records with billing and pharmacy data covering hundreds of millions of patient journeys.
- Investing.com CanadaRead ↗OneMedNet announces 13th channel partner agreement By Investing.com
- Markets InsiderRead ↗OneMedNet Partners to Combine First-Party Multimodal Clinical Data with Comprehensive Patient-Journey AI Analytics, Expanding Commercial Reach Through 13th Channel Partnership
- Business InsiderRead ↗OneMedNet Partners to Combine First-Party Multimodal Clinical Data with Comprehensive Patient-Journey AI Analytics, Expanding Commercial Reach Through 13th Channel Partnership
Details
OneMedNet announced an agreement with an unnamed AI-focused healthcare intelligence company. The company says the partner will resell its U.S.-sourced, de-identified multimodal clinical data together with its own data on claims, pharmacy, encounters and related administrative records.
OneMedNet says its clinical data includes longitudinal records such as physician notes, lab results, imaging and reports, sourced from a network of more than 2,300 healthcare partner sites. The partner’s data, according to OneMedNet, covers hundreds of millions of U.S. patient journeys; the company says its own network includes more than 90 million patient journeys and 270 million studies.
OneMedNet says the combined data is intended for AI model training, clinical development, real-world evidence, market access and health economics research. The company also says the agreement has added approximately 25% to its sales funnel; it did not disclose the partner’s name or financial terms.
Written from coverage as of
Stocks in this story
Change since open: 20 Nov to 21 Nov 2026
Last refresh